Evidence map›Paper›PMID 34602310›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2022

Restrictive allograft syndrome vs bronchiolitis obliterans syndrome: Immunological and molecular characterization of circulating exosomes.

Sandhya Bansal, Ashwini Arjuna, Sudhir Perincheri, Christin Poulson, Ross M Bremner, Michael A Smith, Sofya Tokman, Thalachallour Mohanakumar

Open access · greenAbstract readComparative Study
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Editorial: Antibody-mediated rejection.Frontiers in transplantation · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sandhya BansalNorton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Ashwini ArjunaNorton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Sudhir PerincheriDepartment of Pathology and Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut.
Christin PoulsonNorton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Ross M BremnerNorton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Michael A SmithNorton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Sofya TokmanNorton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Thalachallour MohanakumarNorton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona. Electronic address: tm.kumar@dignityhealth.org.
St. Joseph's Hospital and Medical Center · USYale University · US

Funding

IMMUNE MECHANISMS OF REJECTION IN HUMAN LUNG ALLOGRAFTSR01HL056643 · NHLBI · WASHINGTON UNIVERSITY · PI MOHANAKUMAR, THALACHALLOUR · 1996 to 2015
$6.5M
ALLOANTIBODIES TO MHC INDUCES AUTOIMMUNITY AND OBLITERATIVE AIRWAY DISEASE (OAD)R01HL092514 · NHLBI · WASHINGTON UNIVERSITY · PI MOHANAKUMAR, THALACHALLOUR · 2009 to 2018
$3.0M
EXOSOMES: ROLE IN ALLOGRAFT REJECTION AND POTENTIAL AS A BIOMARKERR21AI123034 · NIAID · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI MOHANAKUMAR, THALACHALLOUR · 2016 to 2017
$397k
NHLBI NIH HHS R01 HL056643NHLBI NIH HHS R01 HL092514NIAID NIH HHS R21 AI123034
6 · The paper itself

Abstract

backgroundChronic lung allograft dysfunction in lung transplant recipients (LTxRs) has 2 phenotypes: obstructive bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Our goal was to define distinct immunologic markers of exosomes from LTxRs with BOS or RAS.

methodsPlasma was collected from LTxRs with BOS (n = 18), RAS (n = 13), and from stable LTxRs (n = 5). Antibodies to lung self-antigens (SAgs) were determined by ELISA. Exosomes were isolated by ultracentrifugation. Donor specific antibodies to HLA were quantified using Luminex. Exosomes were characterized for lung SAgs, transcription factors, 20S proteasome, HLA class I and II, and polymeric immunoglobulin receptor protein using western blot. Exosome miRNA was analyzed using NanoString. The exosome-induced immune response was determined in mice.

resultsLTxRs with RAS, but not BOS, had donor specific antibodies at diagnosis. CIITA, NFkB, polymeric immunoglobulin receptor protein, 20S proteasome, HLA-DQ, and HLA-DR were significantly higher in RAS exosomes than in BOS exosomes. RAS plasma had high levels of proinflammatory cytokines and distinct exosomal miRNA. Immunization of C57BL/6 mice with RAS exosomes showed severe inflammation and peribronchial fibrosis, whereas BOS exosomes induced patchy inflammation and fibrosis.

conclusionLTxRs with BOS or RAS had exosomes with distinct molecular and immunologic profiles. RAS samples had a higher concentration of proinflammatory factors, HLA class II, lung SAgs, and antibodies to HLA class II molecules, indicating severe allograft injury. Mice immunized with RAS exosomes developed lesions in airways, pleura, interlobular septum, and alveoli, whereas BOS exosomes induced mild to patchy inflammation with lung fibrosis.

Indexed as

ExosomesLung TransplantationAnimalsBronchiolitis ObliteransHumansLung DiseasesMicePostoperative ComplicationsRetrospective StudiesSyndromebronchiolitis obliterans syndromeexosomeslung transplantationrestrictive allograft syndrome

Identifiers

PMID34602310
PMCPMC11019888
OpenAlexW3201318921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.